Systematic review of resection of primary midgut carcinoid tumour in patients with unresectable liver metastases
- PMID: 22972490
- DOI: 10.1002/bjs.8842
Systematic review of resection of primary midgut carcinoid tumour in patients with unresectable liver metastases
Abstract
Background: Surgery for small intestinal neuroendocrine tumours (SI-NETs) is limited by metastatic disease in most patients. However, resection of the primary lesion alone has been advocated in patients with unresectable liver metastases. The present systematic review investigated the value of surgical resection of the primary lesion in patients with unresectable metastatic disease.
Methods: MEDLINE was searched for studies reporting the outcome of patients with SI-NETs and unresectable liver metastases where there was an explicit comparison between resection of the primary lesion alone and no resection. The primary outcome was overall survival. Secondary outcomes were progression-free survival, treatment-related mortality and relief of symptoms.
Results: Meta-analysis was not possible, but six studies were analysed qualitatively to highlight useful information. Possible confounders in these studies were the inclusion of patients with other primary tumour sites, unknown primary tumour or non-metastatic disease. Bearing in mind these limitations, there was a clear trend towards longer survival in patients who underwent surgical resection in all studies; their median overall survival ranged from 75 to 139 months compared with 50-88 months in patients who did not have resection. The difference between the two groups was statistically significant in three studies. Data on symptomatic improvement were scarce and did not suggest a clear benefit of surgery. Surgery-related mortality seemed low.
Conclusion: Available data suggest a possible benefit of resection of the primary lesion in patients with unresectable liver metastases, but the studies have several limitations and the results should therefore be considered with caution.
Copyright © 2012 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
Comment in
-
Systematic review of resection of primary midgut carcinoid tumour in patients with unresectable liver metastases (Br J Surg 2012; 99: 1480-1486).Br J Surg. 2012 Nov;99(11):1486-7. doi: 10.1002/bjs.8913. Br J Surg. 2012. PMID: 23027070 No abstract available.
Similar articles
-
Role of resection of the primary pancreatic neuroendocrine tumour only in patients with unresectable metastatic liver disease: a systematic review.Neuroendocrinology. 2011;93(4):223-9. doi: 10.1159/000324770. Epub 2011 Feb 25. Neuroendocrinology. 2011. PMID: 21358176 Review.
-
Systematic review of resecting primary tumor in MNETs patients with unresectable liver metastases.Oncotarget. 2017 Mar 7;8(10):17396-17405. doi: 10.18632/oncotarget.14156. Oncotarget. 2017. PMID: 28030811 Free PMC article. Review.
-
Systematic review of resection of primary midgut carcinoid tumour in patients with unresectable liver metastases (Br J Surg 2012; 99: 1480-1486).Br J Surg. 2012 Nov;99(11):1486-7. doi: 10.1002/bjs.8913. Br J Surg. 2012. PMID: 23027070 No abstract available.
-
Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases.World J Surg. 2002 Aug;26(8):991-7. doi: 10.1007/s00268-002-6630-z. Epub 2002 May 21. World J Surg. 2002. PMID: 12016480
-
Role of palliative resection of the primary tumour in advanced pancreatic and small intestinal neuroendocrine tumours: A systematic review and meta-analysis.Eur J Surg Oncol. 2017 Oct;43(10):1808-1815. doi: 10.1016/j.ejso.2017.05.016. Epub 2017 May 25. Eur J Surg Oncol. 2017. PMID: 28583792 Review.
Cited by
-
Morbidity and Outcomes of Primary Tumor Management in Patients with Widely Metastatic Well-Differentiated Small Bowel Neuroendocrine Tumors.Ann Surg Oncol. 2024 Apr;31(4):2337-2348. doi: 10.1245/s10434-023-14637-3. Epub 2023 Nov 30. Ann Surg Oncol. 2024. PMID: 38036927
-
ASO Author Reflections: Patient-Reported Quality of Life in Patients with Neuroendocrine Tumors Following Surgical Resection.Ann Surg Oncol. 2023 Oct;30(11):6786. doi: 10.1245/s10434-023-13787-8. Epub 2023 Jul 2. Ann Surg Oncol. 2023. PMID: 37394669 No abstract available.
-
Surgery Improves Patient-Reported Outcomes in Patients with Intestinal and Pancreatic NETs: A Prospective Analysis.Ann Surg Oncol. 2023 Oct;30(11):6777-6785. doi: 10.1245/s10434-023-13729-4. Epub 2023 Jun 22. Ann Surg Oncol. 2023. PMID: 37349613
-
Prognostic differences in grading and metastatic lymph node pattern in patients with small bowel neuroendocrine tumors.Langenbecks Arch Surg. 2023 Jun 19;408(1):237. doi: 10.1007/s00423-023-02956-8. Langenbecks Arch Surg. 2023. PMID: 37332044 Free PMC article.
-
Defining a New Classification System for the Surgical Management of Neuroendocrine Tumor Liver Metastases.J Clin Med. 2023 Mar 23;12(7):2456. doi: 10.3390/jcm12072456. J Clin Med. 2023. PMID: 37048539 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical